Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Chow

Showing results (701-710 of 736) with videos related to

Pageof 74
Sort By:
Nature Communications|February 9, 2021
Incorporation of sensing modalities into de novo designed fluorescence-activating proteinsJason C Klima, Lindsey A Doyle, Justin Daho Lee, et al.
Nature|April 5, 2023
De novo design of modular peptide-binding proteins by superhelical matchingKejia Wu, Hua Bai, Ya-Ting Chang, et al.
Applied and Environmental Microbiology|April 10, 2024
Redefining piscine lactococcosisTaylor I Heckman, Zeinab Yazdi, Caitlin E Older, et al.
Biophysical Journal|October 7, 2004
Imaging cells and tissues with refractive index radiologyY Hwu, W L Tsai, H M Chang, et al.
The Lancet. Oncology|March 15, 2016
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trialDong-Wan Kim, Ranee Mehra, Daniel S W Tan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 8, 2019
Comparing dyadic cognitive behavioral therapy (CBT) with dyadic integrative body-mind-spirit intervention (I-BMS) for Chinese family caregivers of lung cancer patients: a randomized controlled trialDaiming Xiu, Yat-Lui Fung, Bobo Hi-Po Lau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion CohortLaura Q M Chow, Robert Haddad, Shilpa Gupta, et al.
The Lancet. Oncology|November 18, 2021
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion studyNehal J Lakhani, Laura Q M Chow, Justin F Gainor, et al.
The New England Journal of Medicine|March 28, 2014
Ceritinib in ALK-rearranged non-small-cell lung cancerAlice T Shaw, Dong-Wan Kim, Ranee Mehra, et al.
Cancer Medicine|December 8, 2022
Biomarkers predictive of response to pembrolizumab in head and neck cancerDavid G Pfister, Robert I Haddad, Francis P Worden, et al.
Pageof 74

Showing results (701-710 of 736) with videos related to

Sort By:
Pageof 74
Nature Communications|February 9, 2021
Incorporation of sensing modalities into de novo designed fluorescence-activating proteinsJason C Klima, Lindsey A Doyle, Justin Daho Lee, et al.
Nature|April 5, 2023
De novo design of modular peptide-binding proteins by superhelical matchingKejia Wu, Hua Bai, Ya-Ting Chang, et al.
Applied and Environmental Microbiology|April 10, 2024
Redefining piscine lactococcosisTaylor I Heckman, Zeinab Yazdi, Caitlin E Older, et al.
Biophysical Journal|October 7, 2004
Imaging cells and tissues with refractive index radiologyY Hwu, W L Tsai, H M Chang, et al.
The Lancet. Oncology|March 15, 2016
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trialDong-Wan Kim, Ranee Mehra, Daniel S W Tan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 8, 2019
Comparing dyadic cognitive behavioral therapy (CBT) with dyadic integrative body-mind-spirit intervention (I-BMS) for Chinese family caregivers of lung cancer patients: a randomized controlled trialDaiming Xiu, Yat-Lui Fung, Bobo Hi-Po Lau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion CohortLaura Q M Chow, Robert Haddad, Shilpa Gupta, et al.
The Lancet. Oncology|November 18, 2021
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion studyNehal J Lakhani, Laura Q M Chow, Justin F Gainor, et al.
The New England Journal of Medicine|March 28, 2014
Ceritinib in ALK-rearranged non-small-cell lung cancerAlice T Shaw, Dong-Wan Kim, Ranee Mehra, et al.
Cancer Medicine|December 8, 2022
Biomarkers predictive of response to pembrolizumab in head and neck cancerDavid G Pfister, Robert I Haddad, Francis P Worden, et al.
Pageof 74